



ASX Announcement

8 January 2020

## **Release of Shares from Voluntary Escrow**

**Creso Pharma Limited** (ASX: “CPH”, the “Company” or “Creso”) advises in accordance with Listing Rule 3.10A, that 500,000 fully paid ordinary shares (“Shares”) will be released from voluntary escrow on Thursday, 16 January 2020.

The Company applied for, and was subsequently granted, quotation of the Shares on 2 December 2019. Holding locks applicable to the abovementioned shares will be lifted prior to the commencement of trade on Thursday, 16 January 2020.

As of the date of this release, the Company has no further securities subject to escrow restrictions.

### **Authority and Contact Details**

This announcement has been authorised for release by Dr Miri Halperin Wernli, CEO and Managing Director of Creso Pharma Limited.

### **Corporate Enquiries:**

EverBlu Capital  
Level 39, Aurora Place  
88 Phillip Street, Sydney NSW 2000  
E: [info@everblucapital.com](mailto:info@everblucapital.com)  
P: +61 2 8249 000

### **About Creso Pharma Ltd**

([www.cresopharma.com](http://www.cresopharma.com))

Creso brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.